One Roof, Two Capabilities: Why Synthetic DNA + AAV Manufacturing Belongs Together
June 18, 2026
AAV is one of the most widely used delivery platforms in gene therapy, supporting approved treatments for inherited retinal...
Read more →In the first post in this series, we looked at the manufacturing landscape for advanced therapies and what the FDA data tells us about why CMC strategy is so consequential to...
Read More →June 18, 2026
AAV is one of the most widely used delivery platforms in gene therapy, supporting approved treatments for inherited retinal...
Read more →May 28, 2026
Last November we published POSTmark CAR-T: Delivering Therapies Without Delay, arguing that manufacturing continuity—not...
Read more →April 27, 2026
At Advanced Therapies Week 2026, our Chief Technology Officer, Gregg Nyberg, joined a panel of industry leaders to discuss how...
Read more →April 02, 2026
Your science is ready.
The mechanism is well-characterized, the preclinical data is compelling, and the clinical development...
Read more →February 26, 2026
Extracellular vesicles have been a subject of scientific fascination for decades. For most of that time, they were studied...
Read more →January 22, 2026
In today’s rapidly evolving biotech landscape, the efficient flow and integration of data across various systems and functions...
Read more →December 15, 2025
Cell and gene therapies (CGTs) have advanced from conceptual promise to clinical reality, with dozens of approved products and...
Read more →December 02, 2025
Advanced therapies present unique challenges from both a regulatory and a chemistry, manufacturing, and controls (CMC)...
Read more →November 12, 2025
CAR-T therapies have redefined cancer treatment, moving from bold hypothesis to frontline standard in less than a decade. With...
Read more →